Central retinal artery occlusion (CRAO) is an ophthalmologic emergency that can lead to irreversible loss of vision. Intravenous thrombolysis (IVT) has been used experimentally for its treatment. Our study aimed to evaluate the effect of emergency IVT on CRAO and its impact on visual acuity outcomes. We conducted a retrospective observational study of patients with CRAO. A total of 46 patients with CRAO were analysed; 16 patients received IVT treatment (IVT group) while 30 did not (no-IVT group). Seven patients from the IVT group received IVT early, within 4.5 hours (h) after the onset of symptoms (early-IVT), and 9 patients received it beyond this timeframe (late-IVT). The median time-to-hospital was 8.5 h: 3 h for the IVT group and 24 h for the no-IVT group. The median time-to-treatment was 5 h. The median outcome of visual acuity was 0.05 in the early-IVT, 0.025 in the late-IVT, and 0.01 in the no-IVT group. Among patients who received IVT early, 86% exhibited significant visual improvement. This improvement was four-fold greater compared to all other groups (p = 0.040), including the late-IVT (p = 0.011) and no-IVT groups (p = 0.023). No complications of the treatment were reported. Our study confirms that the administration of IVT treatment for CRAO within the 4.5-h time window is both safe and effective.

Department of Ophthalmology 2nd Faculty of Medicine Charles University and Motol University Hospital Prague 5 Uvalu 84 150 06 Prague Czech Republic

Department of Probability and Mathematical Statistics Faculty of Mathematics and Physics Charles University Prague Prague Czech Republic

Zobrazit více v PubMed

Mac Grory B, Schrag M, Biousse V, et al. Management of central retinal artery occlusion: A scientific statement from the American heart association. Stroke. 2021;52:e282–e294. doi: 10.1161/STR.0000000000000366. PubMed DOI

Schumacher M, Schmidt D, Jurklies B, et al. Central retinal artery occlusion: Local intra-arterial fibrinolysis versus conservative treatment, a multicenter randomized trial. Ophthalmology. 2010;117(7):1367–1375. doi: 10.1016/j.ophtha.2010.03.061. PubMed DOI

McLeod D, Beatty S. Evidence for an enduring ischaemic penumbra following central retinal artery occlusion, with implications for fibrinolytic therapy. Prog. Retin. Eye Res. 2015;49:82–119. doi: 10.1016/j.preteyeres.2015.06.001. PubMed DOI

Foroozan R, Savino PJ, Sergott RC. Embolic central retinal artery occlusion detected by orbital color Doppler imaging. Ophthalmology. 2002;109(4):744–747. doi: 10.1016/s0161-6420(01)01011-9. PubMed DOI

Hayreh SS, Zimmerman MB. Central retinal artery occlusion: visual outcome. Am. J. Ophthalmol. 2005;140(3):376–391. doi: 10.1016/j.ajo.2005.03.038. PubMed DOI

Mac Grory B, Nackenoff A, Poli S, et al. Intravenous fibrinolysis for central retinal artery occlusion: A cohort study and updated patient-level meta-analysis. Stroke. 2020;51(7):2018–2025. doi: 10.1161/STROKEAHA.119.028743. PubMed DOI

Schrag M, Youn T, Schindler J, et al. Intravenous fibrinolytic therapy in central retinal artery occlusion a patient-level meta-analysis. JAMA Neurol. 2015;72(10):1148–1154. doi: 10.1001/jamaneurol.2015.1578. PubMed DOI

Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 Update to the 2018 guidelines for the early management of acute ischemic stroke: A Guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2019;50:e344–e418. doi: 10.1161/STR.0000000000000211. PubMed DOI

Berge E, Whiteley W, Audebert H, et al. European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. Eur. Stroke J. 2021;6(1):1–62. doi: 10.1177/2396987321989865. PubMed DOI PMC

Heiss WD. The ischemic penumbra: Correlates in imaging and implications for treatment of ischemic stroke. The Johann Jacob Wepfer award 2011. Cerebrovasc. Dis. 2011;32(4):307–320. doi: 10.1159/000330462. PubMed DOI

Préterre C, Godeneche G, Vandamme X, et al. Management of acute central retinal artery occlusion: Intravenous thrombolysis is feasible and safe. Int. J. Stroke. 2017;12(7):720–723. doi: 10.1177/1747493016687578. PubMed DOI

Chen CS, Lee AW, Campbell B, et al. Efficacy of intravenous tissue-type plasminogen activator in central retinal artery occlusion: Report from a randomized, controlled trial. Stroke. 2011;42(8):2229–2234. doi: 10.1161/STROKEAHA.111.613653. PubMed DOI

Schultheiss M, Härtig F, Spitzer MS, et al. Intravenous thrombolysis in acute central retinal artery occlusion: A prospective interventional case series. PLoS ONE. 2018;13(5):e0198114. doi: 10.1371/journal.pone.0198114. PubMed DOI PMC

Holladay JT. Proper method for calculating average visual acuity. J. Refract. Surg. 1997;13(4):388–391. doi: 10.3928/1081-597X-19970701-16. PubMed DOI

Schorr EM, Rossi KC, Stein LK, et al. Characteristics and outcomes of retinal artery occlusion: Nationally representative data. Stroke. 2020;51(3):800–807. doi: 10.1161/STROKEAHA.119.027034. PubMed DOI

Mac Grory B, Lavin P, Kirshner H, Schrag M. Thrombolytic therapy for acute central retinal artery occlusion. Stroke. 2020;51(2):687–695. doi: 10.1161/STROKEAHA.119.027478. PubMed DOI

Lavin P, Patrylo M, Hollar M, et al. Stroke risk and risk factors in patients with central retinal artery occlusion. Am. J. Ophthalmol. 2018;196:96–100. doi: 10.1016/j.ajo.2018.08.027. PubMed DOI

Claessens JLJ, Geuvers JR, Imhof SM, et al. Digital tools for the self-assessment of visual acuity: A systematic review. Ophthalmol. Ther. 2021;10(4):715–730. doi: 10.1007/s40123-021-00360-3. PubMed DOI PMC